Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-10-19 Sale |
2023-10-23 4:23 pm |
RVL Pharmaceuticals plc | RVLP | Harsaul Foundation 10% Owner |
14,122,659 | $0.04108 | $580,147 | 4,941,101 (Indirect) |
View |
| 2023-10-19 Sale |
2023-10-23 1:06 pm |
RVL Pharmaceuticals plc | RVLP | Altchem Ltd Orbit Co-Invest A-1 LLC 10% Owner |
14,122,659 | $0.04108 | $580,147 | 6,123,344 (Indirect Direct) |
View |
| 2023-10-18 Sale |
2023-10-20 3:59 pm |
RVL Pharmaceuticals plc | RVLP | Harsaul Foundation 10% Owner |
3,421,537 | $0.0646 | $221,031 | 19,063,760 (Indirect) |
View |
| 2023-10-18 Sale |
2023-10-20 1:36 pm |
RVL Pharmaceuticals plc | RVLP | Altchem Ltd Orbit Co-Invest A-1 LLC 10% Owner |
3,421,537 | $0.0646 | $221,031 | 20,246,003 (Indirect Direct) |
View |
| 2022-08-08 Purchase |
2022-08-09 5:23 pm |
RVL Pharmaceuticals plc | RVLP | Schaub James EVP and COO |
150,000 | $1.55 | $232,500 | 540,020 (Direct) |
View |
| 2022-08-08 Purchase |
2022-08-09 5:22 pm |
RVL Pharmaceuticals plc | RVLP | MARKISON BRIAN A Chief Executive Officer |
850,000 | $1.55 | $1,317,500 | 2,976,020 (Direct) |
View |
| 2022-08-08 Purchase |
2022-08-09 5:21 pm |
RVL Pharmaceuticals plc | RVLP | Burgstahler David F Director 10% Owner |
8,000,000 | $1.55 | $12,400,000 | 24,763,859 (Indirect) |
View |
| 2022-08-08 Purchase |
2022-08-09 5:19 pm |
RVL Pharmaceuticals plc | RVLP | Venkataraman Sriram Director 10% Owner |
8,000,000 | $1.55 | $12,400,000 | 24,763,859 (Indirect) |
View |
| 2022-08-08 Purchase |
2022-08-09 5:18 pm |
RVL Pharmaceuticals plc | RVLP | Avista Healthcare Partners L.P. Avista Healthcare Partners GP Ltd. Avista Capital Partners III GP L.P. Orbit Co-Invest III LLC 10% Owner |
8,000,000 | $1.55 | $12,400,000 | 24,763,859 (Indirect Direct) |
View |
| 2021-12-16 Purchase |
2021-12-20 5:03 pm |
Osmotica Pharmaceuticals plc | OSMT | Schaub James EVP and COO |
93,800 | $1.07 | $100,366 | 405,900 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-08-15 Other |
2023-08-17 5:04 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Avista Healthcare Partners GP Ltd. Avista Healthcare Partners L.P. 10% Owner |
23,730,864 | $0 | 23,730,864 (Indirect) |
View |
| 2023-08-10 Tax Withholding |
2023-08-14 5:35 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Lask Alisa Director |
12,000 | $0.49 | 112,557 (Direct) |
View |
| 2023-07-05 Option Award |
2023-07-11 9:17 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | DeBiasi Michael J. Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-07-05 Option Award |
2023-07-11 9:16 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | COWAN GREGORY L Director |
40,000 | $0 | 90,055 (Direct) |
View |
| 2023-07-05 Option Award |
2023-07-11 9:15 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Lask Alisa Director |
40,000 | $0 | 124,557 (Direct) |
View |
| 2023-05-18 Tax Withholding |
2023-05-22 9:21 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Schaub James EVP and COO |
5,577 | $0.87 | 524,835 (Direct) |
View |
| 2023-05-18 Tax Withholding |
2023-05-22 9:18 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Klein Christopher General Counsel & Secretary |
5,447 | $0.87 | 180,573 (Direct) |
View |
| 2023-01-27 Other |
2023-01-30 5:29 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Burgstahler David F Director 10% Owner |
1,032,995 | $0 | 24,763,859 (Indirect) |
View |
| 2023-01-27 Other |
2023-01-30 5:28 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Venkataraman Sriram Director 10% Owner |
1,032,995 | $0 | 24,763,859 (Indirect) |
View |
| 2023-01-27 Other |
2023-01-30 5:27 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Avista Capital Partners III GP L.P. Orbit Co-Invest III LLC Avista Healthcare Partners GP Ltd. Avista Healthcare Partners L.P. 10% Owner |
1,032,995 | $0 | 24,763,859 (Indirect) |
View |
| 2023-01-24 Tax Withholding |
2023-01-26 5:16 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Klein Christopher General Counsel & Secretary |
9,608 | $1.26 | 186,020 (Direct) |
View |
| 2023-01-24 Tax Withholding |
2023-01-26 5:15 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Schaub James EVP and COO |
9,608 | $1.26 | 530,412 (Direct) |
View |
| 2022-08-10 Option Award |
2022-08-12 4:07 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Lask Alisa Director |
75,000 | $0 | 84,557 (Direct) |
View |
Ownership |
2022-08-12 4:05 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Lask Alisa Director |
0 | $0 | 9,557 (Direct) |
View |
Ownership |
2022-08-12 11:37 am |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Athyrium Opportunities IV Acquisition 2 LP Athyrium Opportunities IV Co-invest 2 LP Athyrium Opportunities Associates IV LP Athyrium Opportunities Associates IV GP LLC Athyrium Funds GP Holdings LLC Athyrium Opportunities Associates IV Co-Invest LLC Ferrell Jeffrey 10% Owner |
0 | $0 | 16,600,444 (Indirect) |
View |
| 2022-05-18 Tax Withholding |
2022-05-20 4:28 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | deVries Tina Marie EVP, Research & Development |
5,447 | $1.4 | 136,141 (Direct) |
View |
| 2022-05-18 Tax Withholding |
2022-05-20 4:27 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Klein Christopher General Counsel & Secretary |
6,127 | $1.4 | 195,628 (Direct) |
View |
| 2022-05-18 Tax Withholding |
2022-05-20 4:25 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Schaub James EVP and COO |
6,273 | $1.4 | 390,020 (Direct) |
View |
| 2022-01-24 Tax Withholding |
2022-01-26 4:31 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Einhorn Andrew J. Chief Financial Officer |
9,607 | $1.13 | 164,325 (Direct) |
View |
| 2022-01-24 Tax Withholding |
2022-01-26 4:31 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Klein Christopher General Counsel & Secretary |
9,607 | $1.13 | 201,755 (Direct) |
View |
| 2022-01-24 Tax Withholding |
2022-01-26 4:31 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | deVries Tina Marie EVP, Research & Development |
9,607 | $1.13 | 141,588 (Direct) |
View |
| 2022-01-24 Tax Withholding |
2022-01-26 4:30 pm |
N/A N/A |
RVL Pharmaceuticals plc | RVLP | Schaub James EVP and COO |
9,607 | $1.13 | 396,293 (Direct) |
View |
| 2021-11-04 Option Award |
2021-11-08 4:09 pm |
N/A 2031-11-04 |
Osmotica Pharmaceuticals plc | OSMT | deVries Tina Marie EVP, Research & Development |
216,944 | $0 | 216,944 (Direct) |
View |
| 2021-11-04 Option Award |
2021-11-08 4:07 pm |
N/A 2031-11-04 |
Osmotica Pharmaceuticals plc | OSMT | Schaub James EVP and COO |
249,814 | $0 | 249,814 (Direct) |
View |
| 2021-11-04 Option Award |
2021-11-08 4:06 pm |
N/A 2031-11-04 |
Osmotica Pharmaceuticals plc | OSMT | Klein Christopher General Counsel & Secretary |
249,814 | $0 | 249,814 (Direct) |
View |
| 2021-11-04 Option Award |
2021-11-08 4:06 pm |
N/A 2031-11-04 |
Osmotica Pharmaceuticals plc | OSMT | Einhorn Andrew J. Chief Financial Officer |
249,814 | $0 | 249,814 (Direct) |
View |
| 2021-11-04 Option Award |
2021-11-08 4:05 pm |
N/A 2031-11-04 |
Osmotica Pharmaceuticals plc | OSMT | MARKISON BRIAN A Chief Executive Officer |
615,000 | $0 | 615,000 (Direct) |
View |
| 2021-08-27 Tax Withholding |
2021-09-03 4:02 pm |
N/A N/A |
Osmotica Pharmaceuticals plc | OSMT | COWAN GREGORY L Director |
5,506 | $3.31 | 50,055 (Direct) |
View |
| 2021-08-27 Tax Withholding |
2021-09-03 4:01 pm |
N/A N/A |
Osmotica Pharmaceuticals plc | OSMT | WEISS FRED G Director |
5,506 | $3.31 | 118,466 (Direct) |
View |